Sanpraz

Sanpraz – pharmacological drug from group of inhibitors of a proton pomp for treatment of cankers of digestive tract.

Structure and form of release

According to the instruction Sanpraz is issued in the form of tablets, coated and in the form of lyophilisate for intravenous administration. Active ingredient – пантопразол.

Sanpraz's tablets round, biconvex, are covered with a yellow kishechnorastvorimy cover. 1 tablet contains 40 mg of a pantoprazol and auxiliary components (magnesium oxide, кросповидон, calcium carbonic, sodium lauryl sulfate, calcium stearate, colloid silicon dioxide, кросповидон. polymethacrylate, triethyl citrate, talc, macrogoal, titanium dioxide, isopropyl alcohol, water).

Sanpraz in the form of lyophilisate is issued in glass bottles. 1 bottle (volume of 10 ml) contains 40 mg of a pantoprazol. In packaging the ampoule with solvent (sodium chloride and water) of 10 ml is applied to a bottle with lyophilisate. In a cardboard box 1 bottle with lyophilisate and 1 ampoule with solvent.

Pharmacological action of Sanpraz

According to the instruction Sanpraz is inhibitor of a proton pomp, drug blocks secretion of hydrochloric acid in its final stage, and thus influences basal and stimulated secretion. Sanpraz's use at treatment of the peptic ulcer associated with a helikobakter promotes increase in sensitivity of this microorganism to antibacterial drugs. Sanpraz does not exert impact on motility of the alimentary system. Secretory activity of a stomach is recovered after the end of reception of this drug in 3 days.

According to the instruction Sanpraz has no cumulative effect. Drug generally is removed by kidneys.

Indications to use

• treatment of a peptic ulcer (with chronic stomach ulcer or a duodenum in an aggravation stage);
• treatment of erosive changes mucous stomach and duodenum (acute ulcers of various genesis, erosive gastritis);
• erosive reflux esophagitis, gastroesophageal reflux disease (GERB);
• gastrinoma of a pancreas (Zollingera-Elisson's syndrome);
• prevention of erosive and ulcer complications from the alimentary system in the early postoperative period at patients with the increased risk.

Contraindications to Sanpraz's use

• hypersensitivity to the making drug components;
• malignant new growths of a digestive tract;
• disturbance of digestion of a psychogenic origin;
• the feeding period a breast, children's age up to 18 years.

With care it is necessary to apply Sanpraz during pregnancy and at symptoms of a liver failure.

Use during pregnancy and a lactation

At clinical animal experiments the insignificant embriotoksichesky effect is revealed. Therefore Sanpraz's use during pregnancy is possible only if the potential advantage exceeds risk for a fruit. There are no data on Sanpraz's penetration into breast milk. It is recommended to stop breastfeeding for the period of treatment by this drug.

Route of administration and Sanpraz's doses

According to the instruction Sanpraz in tablets it is necessary to accept 1-2 times a day, without chewing, washing down with enough water. Drug should be used in 1 hour prior to meal. Sanpraz's reception, according to reviews, is well transferred by patients and effectively eliminates clinical symptoms of a disease.

At treatment of a peptic ulcer and erosive defeats mucous upper parts of digestive tract Sanpraz is recommended to accept on 40-80 mg a day for 14 days. In case of need the course of treatment can be prolonged up to 4-8 weeks (after consultation of the doctor).

At treatment a reflux esophagitis Sanpraz is appointed on 40 mg (1 tablet) for 4-6 weeks once a day.

At patients with the broken function of a liver Sanpraz's dose should not exceed 20-40 mg a day (drug can be accepted every other day), during treatment it is necessary to control biochemical indicators of blood (bilirubin, ALT, nuclear heating plant, ShchF).

Sanpraz in the form of lyophilisate for preparation of solution is intended only for intravenous administration. The usual dose of the administered drug makes 40 mg (1 bottle) a day. Duration of a course of intravenous infusions makes 7-10 days, further it is necessary to pass to oral administration of Sanpraz.

At treatment of a syndrome of Zollinger - Elisson and other morbid conditions with hypersecretion of hydrochloric acid the daily dose of Sanpraz can be increased to 80 mg (2 times a day are entered). Maximum daily dose of this drug of 160 mg.

The patient of advanced age the recommended daily dose of Sanpraz makes 40 mg.

Lyophilisate before use should be mixed with solvent (10 ml). The received solution is entered struyno (within 2-5 minutes) or kapelno at infusion (mixes up from 100 ml of normal saline solution of sodium of chloride or 5% glucose solution).

Side effect

According to responses, Sanpraz extremely seldom causes side reactions at observance of the recommended dosages.

The following side effects are possible: headache, nausea, abdominal pains, diarrhea/lock, meteorism. According to reviews Sanpraz seldom caused dryness in a mouth, a depression, joint pains, hallucinations (in predisposed patients).

Seldom or never drug caused allergic reactions (including an acute anaphylaxis), a liver failure, intersticial nephrite, a leukopenia, thrombocytopenia, heavy skin reactions (a Lyell's disease, Stephens-Johnson's syndrome).

The person has no messages on overdose by this drug. The entered doses to 240 mg were transferred to days well. Overdose treatment – symptomatic.

Interaction with other medicines

According to the instruction Sanpraz can reduce absorbability of drugs at which bioavailability is directly connected with acidity of a gastric juice (for example, кетокеназол, ритонавир, iron salts).

At simultaneous use with warfarin increase in a prothrombin time is noted that can cause bleeding. Therefore at a combination of these two drugs it is necessary to control a prothrombin time.

With such drugs as digoxin, метопролол, nifedipine, diclofenac, феназол, piroxicam, Naproxenum, amoxicillin, кларитромицин, glibenclamide, diazepam, карбмазепин, цизаприд, midazolam, metronidazole, theophylline clinically significant interaction is not revealed.

Sanpraz's analogs

Sanpraz's analogs are drugs from group of inhibitors of a proton pomp: пантопразол, zipantola, nolpaza, kontrolok, pan-basin, pizhenum-sanovel. Before Sanpraz's replacement with an analog it is necessary to consult with the doctor.

Special instructions

Before an initiation of treatment of a peptic ulcer of a stomach it is necessary to exclude probability of malignant nature of process as treatment by Sanpraz can grease a clinical picture and delay statement of the correct diagnosis. Carrying out endoscopic control before treatment by Sanpraz is obligatory, it will allow to exclude malignant new growths of upper parts of the alimentary system and will allow to estimate efficiency of the carried-out therapy.

Drug does not influence ability to manage motor transport.